Literature DB >> 17697965

Frequency and targeted detection of HLA-DPB1 T cell epitope disparities relevant in unrelated hematopoietic stem cell transplantation.

Elisabetta Zino1, Luca Vago, Simona Di Terlizzi, Benedetta Mazzi, Laura Zito, Elisabetta Sironi, Silvano Rossini, Chiara Bonini, Fabio Ciceri, Maria Grazia Roncarolo, Claudio Bordignon, Katharina Fleischhauer.   

Abstract

The majority of unrelated donor (UD) hematopoietic stem cell (HSC) transplants are performed across HLA-DP mismatches, which, if involving disparity in a host-versus-graft (HVG) direction for an alloreactive T cell epitope (TCE), have been shown by our group to be associated with poor clinical outcome in 2 cohorts of patients transplanted for hematopoietic malignancies and beta-thalassemia, respectively. Using site-directed mutagenesis of DPB1*0901, we show here that the TCE is abrogated by the presence of amino acids LFQG in positions 8-11 of the DP beta-chain. Based on this and on alloreactive T cell responsiveness, we have determined the presence or absence of the TCE for 72 DPB1 alleles reported in the ethnic groups representative of the worldwide UD registries, and predict that 67%-87% (mean 77%) of UD recipient pairs will not present a DPB1 TCE disparity in the HVG direction. We developed and validated in 112 healthy Italian blood donors an innovative approach of DPB1 epitope-specific typing (EST), based on 2 PCR reactions. Our data show that DPB1 TCE disparities may hamper the clinical success of a considerable number of transplants when DPB1 matching is not included into the donor selection criteria, and that a donor without DPB1 TCE disparities in the HVG direction can be found for the majority of patients. Moreover, the study describes the first protocol of targeted epitope-specific DPB1 donor-recipient matching for unrelated HSC transplantation. This protocol will facilitate large-scale retrospective clinical studies warranted to more precisely determine the clinical relevance of DPB1 TCE disparities in different transplant conditions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17697965     DOI: 10.1016/j.bbmt.2007.05.010

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  14 in total

1.  Chromosome Y-encoded antigens associate with acute graft-versus-host disease in sex-mismatched stem cell transplant.

Authors:  Wei Wang; Hu Huang; Michael Halagan; Cynthia Vierra-Green; Michael Heuer; Jason E Brelsford; Michael Haagenson; Richard H Scheuermann; Amalio Telenti; William Biggs; Nathaniel M Pearson; Julia Udell; Stephen Spellman; Martin Maiers; Caleb J Kennedy
Journal:  Blood Adv       Date:  2018-10-09

2.  Predicting relevant immunogenetic disparities.

Authors:  Joseph Pidala; Claudio Anasetti
Journal:  Blood       Date:  2016-07-07       Impact factor: 22.113

3.  Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study.

Authors:  Katharina Fleischhauer; Bronwen E Shaw; Theodore Gooley; Mari Malkki; Peter Bardy; Jean-Denis Bignon; Valérie Dubois; Mary M Horowitz; J Alejandro Madrigal; Yasuo Morishima; Machteld Oudshoorn; Olle Ringden; Stephen Spellman; Andrea Velardi; Elisabetta Zino; Effie W Petersdorf
Journal:  Lancet Oncol       Date:  2012-02-15       Impact factor: 41.316

4.  Directionality of non-permissive HLA-DPB1 T-cell epitope group mismatches does not improve clinical risk stratification in 8/8 matched unrelated donor hematopoietic cell transplantation.

Authors:  K Fleischhauer; K W Ahn; H L Wang; L Zito; P Crivello; C Müller; M Verneris; B E Shaw; J Pidala; M Oudshorn; S J Lee; S R Spellman
Journal:  Bone Marrow Transplant       Date:  2017-06-05       Impact factor: 5.483

5.  A combined DPA1~DPB1 amino acid epitope is the primary unit of selection on the HLA-DP heterodimer.

Authors:  Jill A Hollenbach; Abeer Madbouly; Loren Gragert; Cynthia Vierra-Green; Susan Flesch; Stephen Spellman; Ann Begovich; Harriet Noreen; Elizabeth Trachtenberg; Tom Williams; Neng Yu; Bronwen Shaw; Katharina Fleischhauer; Marcelo Fernandez-Vina; Martin Maiers
Journal:  Immunogenetics       Date:  2012-04-13       Impact factor: 2.846

Review 6.  Optimal HLA matching in hematopoietic cell transplantation.

Authors:  Effie W Petersdorf
Journal:  Curr Opin Immunol       Date:  2008-08-08       Impact factor: 7.486

7.  Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation.

Authors:  Joseph Pidala; Stephanie J Lee; Kwang Woo Ahn; Stephen Spellman; Hai-Lin Wang; Mahmoud Aljurf; Medhat Askar; Jason Dehn; Marcelo Fernandez Viña; Alois Gratwohl; Vikas Gupta; Rabi Hanna; Mary M Horowitz; Carolyn K Hurley; Yoshihiro Inamoto; Adetola A Kassim; Taiga Nishihori; Carlheinz Mueller; Machteld Oudshoorn; Effie W Petersdorf; Vinod Prasad; James Robinson; Wael Saber; Kirk R Schultz; Bronwen Shaw; Jan Storek; William A Wood; Ann E Woolfrey; Claudio Anasetti
Journal:  Blood       Date:  2014-08-26       Impact factor: 22.113

8.  In silico prediction of nonpermissive HLA-DPB1 mismatches in unrelated HCT by functional distance.

Authors:  Esteban Arrieta-Bolaños; Pietro Crivello; Bronwen E Shaw; Kwang Woo Ahn; Hai-Lin Wang; Michael R Verneris; Katharine C Hsu; Joseph Pidala; Stephanie J Lee; Katharina Fleischhauer; Stephen R Spellman
Journal:  Blood Adv       Date:  2018-07-24

Review 9.  Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT.

Authors:  Edus H Warren; Xinyi Cindy Zhang; Shuying Li; Wenhong Fan; Barry E Storer; Jason W Chien; Michael J Boeckh; Lue Ping Zhao; Paul J Martin; John A Hansen
Journal:  Blood       Date:  2012-08-02       Impact factor: 22.113

10.  Identification of high-risk amino-acid substitutions in hematopoietic cell transplantation: a challenging task.

Authors:  S R Marino; S M Lee; T A Binkowski; T Wang; M Haagenson; H-L Wang; M Maiers; S Spellman; K van Besien; S J Lee; T Karrison; A Artz
Journal:  Bone Marrow Transplant       Date:  2016-05-23       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.